![]() |
市場調査レポート
商品コード
1576940
血行動態モニタリングシステム:市場考察、競合情勢、市場予測(2030年)Hemodynamic Monitoring Systems - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
||||||
カスタマイズ可能
適宜更新あり
|
血行動態モニタリングシステム:市場考察、競合情勢、市場予測(2030年) |
出版日: 2024年10月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
世界の血行動態モニタリングシステムの市場規模は、2023年に9億2,400万米ドルであり、2030年までに13億3,000万米ドルに達すると予測され、2024年~2030年の予測期間にCAGRで6.29%の成長が見込まれます。心不全や高血圧などの心血管疾患の有病率の増加は、これらの疾患を効果的に管理し、患者の転帰を改善する継続的で正確なモニタリングの必要性を強く示しています。同時に、患者と医療提供者の双方における健康意識の高まりが、早期の発見と介入を可能にする先進のモニタリングソリューションに対する需要を促進しています。さらに、センサーの強化や電子カルテとの統合などの技術革新を特徴とする、市場の主要企業による製品開発の増加は、より精密で使いやすく統合されたモニタリングソリューションを提供することにより、市場の成長をさらに後押ししています。これらの要因が相まって、血行動態モニタリングシステムの採用拡大と進歩に寄与し、2024年~2030年の予測期間に市場成長を促進します。
血行動態モニタリングシステムの市場力学
British Heart Foundationの近年のデータ(2024年)によると、世界全体で約6億2,000万人、約13人に1人が心疾患および循環器疾患を抱えています。また、同資料によると、2021年の心疾患および循環器疾患の有病率は欧州で1億人、アジア・オーストラリアで3億4,000万人でした。
さらに、British Heart Foundationが提供した近年のデータ(2024年)によると、冠動脈(虚血性)心疾患は、世界中でもっとも多く診断され、世界中で推定2億人が罹患しています。約1億1,000万人の男性と8,000万人の女性が罹患しています。さらに、約5,600万人の女性と4,500万人の男性が脳卒中の生存者でした。世界中で少なくとも1,300万人が先天性心疾患を患っていると推定され、さらに数百万人が診断されていない可能性があります。
世界保健機関(WHO)の最新のデータ(2023年)によると、世界の30歳~79歳の成人の高血圧患者は推定12億8,000万人で、そのほとんど(3分の2)が低中所得国に居住しています。高血圧の成人の推定46%は自分の状態に気づいておらず、診断を受けて治療を受けているのは半数以下(42%)でした。心臓病、心不全、高血圧などの心血管疾患が世界的に流行するにつれて、患者の心血管の健康状態をリアルタイムで把握できる先進のモニタリングソリューションに対する需要が高まります。血行動態モニタリングシステムは、血圧、心拍出量、体液の状態などの主な生理学的パラメーターを追跡するための重要な機能を提供します。臨床医が血行動態の変化を迅速かつ正確にモニターできるようにすることで、これらのシステムは治療計画の最適化、合併症の予防、患者全体の転帰の改善に役立ち、世界中の血行動態モニタリングシステム市場全体を拡大させています。
上記の要因に加えて、歩留まりや診断精度を向上させる新技術の開発など、血行動態モニタリングシステムの分野における技術的進歩も、血行動態モニタリングシステム市場の成長を助けると予測されます。例えば2021年9月、FDAはCaretaker MedicalのVitalStream(TM)ワイヤレスプラットフォームの非侵襲性血圧・血行動態連続モニタリングへの使用を認可しました。
しかし、敗血症、出血、血栓症、精度への懸念など、侵襲性の血行動態モニタリングに伴うリスクが、血行動態モニタリングシステムの成長を抑制すると予測されます。
血行動態モニタリングシステム市場のセグメント分析
血行動態モニタリングシステム市場全体の製品セグメントでは、非侵襲性血行動態モニタリングシステムが2023年に最大のシェアを占めると予測されます。非侵襲性血行動態モニターは、患者の快適性を高め、臨床転帰を改善し、医療のワークフローを合理化する先進のソリューションを提供することで、血行動態モニタリングシステム市場全体を大きく押し上げています。これらのモニターは、侵襲性の処置を必要とせずに正確で継続的な血行動態データを提供するため、患者のリスクを軽減し、不快感を最小限に抑え、合併症の可能性を低下させます。その結果、救急医療や日常的な患者モニタリングなどのさまざまな臨床環境でますます好まれるようになってきています。非侵襲性モニターが血圧、心拍出量、体液の状態などの重要なパラメーターのデータをリアルタイムで提供できることにより、医療提供者はタイムリーで十分な情報に基づいた意思決定を行うことができ、治療戦略を最適化し、患者管理を改善することができます。
当レポートでは、世界の血行動態モニタリングシステム市場について調査分析し、各地域の市場規模と予測、過去3年の製品/技術開発、市場の主要企業、将来の機会などの情報を提供しています。
Hemodynamic Monitoring Systems Market by Product (Systems and Disposables), Type (Invasive Hemodynamic Monitoring, Minimally Invasive Hemodynamic Monitoring, and Non-Invasive Hemodynamic Monitoring), End-User (Hospitals, Ambulatory Care Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the increase in incidence of cardiovascular diseases, growing awareness regarding health, and increase in product development activities by key market players across the globe.
The global hemodynamic monitoring systems market was valued at USD 924 million in 2023, growing at a CAGR of 6.29% during the forecast period from 2024 to 2030, in order to reach USD 1.33 billion by 2030. The growing prevalence of cardiovascular conditions, such as heart failure and hypertension, underscores the need for continuous and accurate monitoring to manage these diseases effectively and improve patient outcomes. Concurrently, heightened health awareness among both patients and healthcare providers drives demand for advanced monitoring solutions that enable early detection and intervention. Furthermore, increased product development by key market players characterized by technological innovations, such as enhanced sensors and integration with electronic health records, further propels market growth by offering more precise, user-friendly, and integrated monitoring solutions. Together, these factors contribute to the expanding adoption and advancement of hemodynamic monitoring systems and propels market growth during forecast period from 2024 to 2030.
Hemodynamic Monitoring Systems Market Dynamics:
According to a recent data provided by British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, lived with heart and circulatory diseases. Additionally, as per the same source, the prevalence of heart and circulatory diseases was 100 million in Europe and 340 million in Asia and Australia in 2021.
Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, was the most commonly diagnosed worldwide, affected an estimated 200 million people globally. Approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.
As per the latest data provided by World Health Organization (2023), an estimated 1.28 billion adults aged 30-79 years worldwide had hypertension, with most (two-thirds) residing in low- and middle-income countries. An estimated 46% of adults with hypertension were unaware of their condition, and less than half (42%) had been diagnosed and treated. As cardiovascular conditions, such as heart disease, heart failure, and hypertension, become more prevalent globally, there is an increased demand for sophisticated monitoring solutions that can provide real-time insights into patients' cardiovascular health. Hemodynamic monitoring systems offer vital capabilities to track key physiological parameters, such as blood pressure, cardiac output, and fluid status, which are crucial for diagnosing, treating, and managing these conditions. By enabling clinicians to monitor changes in hemodynamic status promptly and accurately, these systems help in optimizing treatment plans, preventing complications, and improving overall patient outcomes thereby escalating the overall market of hemodynamic monitoring systems across the globe.
Along with the factors mentioned above, technological advancements in the field of hemodynamic monitoring systems such as the development of new techniques to enhance the yield and diagnostic accuracy are also expected to aid in the growth of the hemodynamic monitoring systems market. For instance, in September 2021, FDA cleared Caretaker Medical's VitalStream(TM) wireless platform for continuous noninvasive blood pressure and hemodynamic monitoring.
However, the risk associated with invasive hemodynamic monitoring, such as sepsis, bleeding, hemorrhage, thrombosis, and accuracy concerns is expected to restrain the growth of hemodynamic monitoring systems.
Hemodynamic Monitoring Systems Market Segment Analysis:
Hemodynamic Monitoring Systems Market by Product (Systems and Disposables), Type (Invasive Hemodynamic Monitoring, Minimally Invasive Hemodynamic Monitoring, and Non-Invasive Hemodynamic Monitoring), End-User (Hospitals, Ambulatory Care Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of the overall hemodynamic monitoring systems market, the non-invasive hemodynamic monitoring systems are expected to hold the largest share in the year 2023. Non-invasive hemodynamic monitors are significantly boosting the overall market for hemodynamic monitoring systems by offering advanced solutions that enhance patient comfort, improve clinical outcomes, and streamline healthcare workflows. These monitors provide accurate and continuous hemodynamic data without the need for invasive procedures, which reduces patient risk, minimizes discomfort, and lowers the potential for complications. As a result, they are becoming increasingly preferred in various clinical settings, including critical care, emergency medicine, and routine patient monitoring. The ability of non-invasive monitors to deliver real-time data on critical parameters such as blood pressure, cardiac output, and fluid status enables healthcare providers to make timely and informed decisions, optimizing treatment strategies and improving patient management.
Consequently, the advancement and integration of these monitors into clinical practice are propelling the market growth by enhancing the overall effectiveness and efficiency of hemodynamic monitoring systems. For instance, in January 2024, Nanowear, a leader in healthcare-at-home remote diagnostics, announced that its nanotechnology-enabled wearable and software platform, SimpleSense(TM), received FDA 510(k) clearance for its novel AI-enabled Software-as-a-Medical Device (SaMD). As the first non-invasive, cuffless, continuous blood pressure monitor and diagnostic, SimpleSense-BP represented a significant advancement in clinical diagnostic management of hypertension, adding to the wearable platform's previously cleared cardiopulmonary diagnostics.
Hence, all the above-mentioned factors are expected to generate considerable revenue of the segment pushing the overall growth of the global hemodynamic monitoring systems market during the forecast period.
North America is expected to dominate the overall hemodynamic monitoring systems market:
Among all the regions, North America is expected to hold the largest share in the global hemodynamic monitoring systems market in 2023. Owing to significant growth factors such as growing prevalence of hypertension and cardiovascular diseases. Additionally, increasing health awareness, technological advancement in hemodynamic monitoring system, and rising government initiatives are expected to aid in the growth of the North American hemodynamic monitoring systems market during the forecast period from 2024 to 2030.
According to the latest data provided by the Centre for Disease Control and Prevention (2023), approximately, 48.1% population of adults age 18 and older in the United States are living with hypertension.
According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.
These conditions necessitate precise and continuous monitoring to manage and mitigate the risks associated with cardiovascular events. As healthcare providers and patients seek effective tools to monitor heart function, blood pressure, and overall cardiovascular health, hemodynamic monitoring systems become essential. These systems provide critical insights into cardiovascular performance, enabling timely interventions and personalized treatment plans. Thus, the increasing burden of these diseases fuels the market of hemodynamic monitoring system as healthcare systems invest in advanced monitoring technologies to improve patient outcomes and manage chronic conditions effectively thereby escalating the market across the region.
Furthermore, the increased emphasis on product development activities and high interest of device manufacturers in accessing local markets further aid in the growth of the regional markets for hemodynamic monitoring systems. For instance, in March 2021, FDA granted De Novo classification to Fifth Eye's continuous hemodynamic status monitoring tool. The analytic for hemodynamic instability tool can identify hemodynamic instability with 96% sensitivity and detect stable patients with 85% specificity. The product launches in the local markets correlate to a significant reduction in costs thereby making them affordable for end-users which in turn drives the product demand in the market.
Therefore, the interplay of above mentioned various factors in the region are expected to boost the North America hemodynamic monitoring systems market during the forecast period.
Hemodynamic Monitoring Systems Market Key Players:
Some of the key market players operating in the hemodynamic monitoring systems market include Edwards Lifesciences Corporation, Getinge AB, Deltex Medical Limited, ICU Medical, Inc., CNSystems Medizintechnik GmbH, Caretaker, LLC, Osypka Medical GmbH, Baxter International Inc. (Cheetah Medical, Inc.), Shenzhen Comen Medical Instruments Co., Ltd., General Meditech Inc., Dragerwerk AG & Co. KGaA, General Electric Company, Smiths Group, Transonic Systems Inc., EMTEL Sliwa sp. K, NIMedical, Masimo (LiDCO Group Plc), Nihon Kohden Corporation, Hemo Sapiens Inc., Koninklijke Philips N.V., and others.
Recent Developmental Activities in the Hemodynamic Monitoring Systems Market:
Key Takeaways From the Hemodynamic Monitoring Systems Market Report Study:
Target Audience who can be Benefited From This Hemodynamic Monitoring Systems Market Report Study:
Frequently Asked Questions for the Hemodynamic Monitoring Systems Market: